How long has Wegovy been out, and what does that mean for you?

When the evidence actually began, and what the trials showed

The story starts earlier than most people expect. Semaglutide as a molecule had already been studied in type 2 diabetes for years before Novo Nordisk ran the STEP programme specifically for weight management. STEP 1, the trial that anchored Wegovy's approval, randomised over 1,900 adults with obesity and ran for 68 weeks; its results, published in the New England Journal of Medicine in 2021, showed an average body-weight reduction of around 15% at the 2.4mg maintenance dose. That figure was striking enough to accelerate regulatory review on both sides of the Atlantic. For context on how the research history stacks up, the full study timeline covers earlier semaglutide work going back further still.

The MHRA granted UK approval in January 2023. NHS England followed with interim commissioning guidance, and by spring 2023 Wegovy was reachable (in theory) through specialist weight management services. In practice, waiting lists meant many people could not access it quickly. That gap between licence and real-world availability is one reason private prescription routes grew rapidly.

Three years in: what the track record tells you, and where gaps remain

Three years is a reasonable window for post-market data to accumulate, and the picture has largely confirmed the trial results. Regulatory agencies have updated guidance, added new indications, and issued targeted safety communications, the sort of activity you would expect from a medicine in active use, not one being quietly sidelined. In January 2026, the MHRA issued a Drug Safety Update specifically on GLP-1 medicines highlighting acute pancreatitis as an infrequent but serious possibility; severe, persistent stomach pain that may radiate to the back warrants urgent medical attention.

What the three-year track record does not tell you is how Wegovy performs over a longer horizon for any individual. NICE's two-year maximum recommendation under TA875 reflects the evidence available at appraisal; long-term outcomes beyond that window are still being studied, and people who stop treatment often find it helpful to understand how long Wegovy stays in the system once they do. The molecule itself is not new, which gives researchers and clinicians more confidence in the mechanism, semaglutide's broader history stretches back considerably further in the diabetes setting.

The 2026 expansion: a higher dose and a new delivery format

Wegovy's story did not stop at launch. On 14 April 2026, the MHRA approved a single-dose 7.2mg pen, one injection per week, pre-set, with a built-in covered needle that locks after use. Trials of the higher dose reported average weight loss of around 20.7% over 72 weeks, approaching what has been seen with tirzepatide 15mg. The 7.2mg licence covers adults with a BMI of 30 or above; it is not approved for the BMI 27–29.9 band or for the cardiovascular indication. Starting dose remains 0.25mg, with the prescriber titrating upward across several months. Whether a specific dose or pen format is right for any individual is confirmed at consultation, availability and clinical suitability both factor in.

The same year also saw a first for the UK: the MHRA approved an oral semaglutide tablet for weight management in June 2026, making the UK the first country in Europe to licence it. That is a separate product from the injection, with its own dosing schedule and trial data, but it is part of the same expanding picture of semaglutide options. For anyone keeping an eye on how quickly this space moves, the pace since early 2023 has been considerable.

What the timeline means for your decision right now

If you have been waiting to see whether Wegovy had enough of a track record before considering it, three years of post-approval experience (including NICE review, real-world prescribing, and updated regulatory guidance) provides a reasonable foundation. The honest caveat is that the medicine is still on the MHRA's Black Triangle (▼) list, meaning additional monitoring continues; that is standard for newer medicines and does not indicate a problem, but it does mean the picture is still developing.

Timing questions come up often in our consultations: people wonder whether to wait until after a holiday, or until the new month begins. The answer is usually that the right time is when your health situation calls for it, not the calendar. If you are curious about how quickly the medicine typically begins working once started, a detailed breakdown of the timeline to effect covers that question specifically. For a broader comparison of the private cost of treatment, our Wegovy price comparison page sets out what a legitimate prescription-inclusive price looks like and what the range reflects. Wegovy is a prescription-only medicine; a prescriber reviews your full picture before any treatment is issued. If you would like that conversation, speaking to our prescribers is straightforward and free to start.